Malignant Neoplasms of Lip Oral Cavity and Pharynx Recruiting Phase 1 Trials for Everolimus (DB01590)

DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Recruiting1 IdentifierTitlePurposeDrugs
NCT03065387Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTreatment